Hexamer Therapeutics
Hexamer Therapeutics is focused on developing innovative vaccine technologies, including rapid, scalable, and natural peptide-based vaccines. Their mission is to create effective vaccines for COVID-19 variants, emerging infectious diseases, and cancer, utilizing proprietary platform technology combined with advanced AI. They aim to deliver safe, robust, and easily distributable vaccines, with a vision to revolutionize pandemic response and health security.
Industries
Nr. of Employees
small (1-50)
Hexamer Therapeutics
Patents
Products
Self-assembling peptide vaccine platform
A modular vaccine scaffold made from natural peptides that self-assembles and is designed to present conjugated antigenic targets with controlled stoichiometry; intended for rapid generation of vaccine candidates and combination antigen approaches.
SARS-CoV-2 vaccine candidates (peptide-based)
Vaccine candidates targeting SARS-CoV-2 S-protein regions using the peptide scaffold with demonstrated in vitro neutralization and preclinical antibody and T-cell responses.
Personalized neoantigen cancer vaccine development
Modular hapten/scaffold-based approach to create individualized vaccines that present patient-specific tumor neoantigens to stimulate anti-tumor immunity.
Hexamer Vaccine Technology
A self-assembling, natural peptide scaffold platform for building infectious disease and cancer vaccines with stoichiometrically controlled antigen conjugation.
Self-assembling peptide vaccine platform
A modular vaccine scaffold made from natural peptides that self-assembles and is designed to present conjugated antigenic targets with controlled stoichiometry; intended for rapid generation of vaccine candidates and combination antigen approaches.
SARS-CoV-2 vaccine candidates (peptide-based)
Vaccine candidates targeting SARS-CoV-2 S-protein regions using the peptide scaffold with demonstrated in vitro neutralization and preclinical antibody and T-cell responses.
Personalized neoantigen cancer vaccine development
Modular hapten/scaffold-based approach to create individualized vaccines that present patient-specific tumor neoantigens to stimulate anti-tumor immunity.
Hexamer Vaccine Technology
A self-assembling, natural peptide scaffold platform for building infectious disease and cancer vaccines with stoichiometrically controlled antigen conjugation.
Services
Partnerships to co-develop and manufacture peptide-based vaccines using the self-assembling scaffold and partner cGMP peptide manufacturers.
Partnerships to co-develop and manufacture peptide-based vaccines using the self-assembling scaffold and partner cGMP peptide manufacturers.
Expertise Areas
- Peptide-based vaccine platform development
- Rapid vaccine candidate engineering
- Antigen conjugation chemistry for epitope presentation
- Preclinical immunology and neutralization assays
Key Technologies
- Self-assembling peptide scaffolds
- Antigen conjugation with stoichiometric control
- Synthetic/cGMP peptide manufacturing
- Lyophilization for dry-powder vaccines
News & Updates
Hexamer Therapeutics Inc. has a powerful breakthrough technology for the rapid development of safe vaccines against COVID-19 variants and emerging infectious diseases. By combining Hexamer's proprietary vaccine platform and advance AI technology it enables the creation of vaccines that self-assemble into peptides, triggering a robust and durable immune response in patients.
Hexamer Therapeutics Inc. (“HTI”) and Innovative Vaccine Technologies (“IVT”) announce they are collaborating to develop and manufacture a safe, highly scalable and effective novel type of COVID-19 vaccine. This joint effort utilizes HTI’s revolutionary patented vaccine technology consisting of a novel self-assembling vaccine (strings of natural amino acids) combined with an adjuvant proven safe for the elderly, the vaccine sensitive, and the immune compromised.
Hexamer Therapeutics Inc. has a powerful breakthrough technology for the rapid development of safe vaccines against COVID-19 variants and emerging infectious diseases. By combining Hexamer's proprietary vaccine platform and advance AI technology it enables the creation of vaccines that self-assemble into peptides, triggering a robust and durable immune response in patients.
Hexamer Therapeutics Inc. (“HTI”) and Innovative Vaccine Technologies (“IVT”) announce they are collaborating to develop and manufacture a safe, highly scalable and effective novel type of COVID-19 vaccine. This joint effort utilizes HTI’s revolutionary patented vaccine technology consisting of a novel self-assembling vaccine (strings of natural amino acids) combined with an adjuvant proven safe for the elderly, the vaccine sensitive, and the immune compromised.
Hexamer Therapeutics Inc. has a powerful breakthrough technology for the rapid development of safe vaccines against COVID-19 variants and emerging infectious diseases. By combining Hexamer's proprietary vaccine platform and advance AI technology it enables the creation of vaccines that self-assemble into peptides, triggering a robust and durable immune response in patients.
Hexamer Therapeutics Inc. (“HTI”) and Innovative Vaccine Technologies (“IVT”) announce they are collaborating to develop and manufacture a safe, highly scalable and effective novel type of COVID-19 vaccine. This joint effort utilizes HTI’s revolutionary patented vaccine technology consisting of a novel self-assembling vaccine (strings of natural amino acids) combined with an adjuvant proven safe for the elderly, the vaccine sensitive, and the immune compromised.
Hexamer Therapeutics Inc. has a powerful breakthrough technology for the rapid development of safe vaccines against COVID-19 variants and emerging infectious diseases. By combining Hexamer's proprietary vaccine platform and advance AI technology it enables the creation of vaccines that self-assemble into peptides, triggering a robust and durable immune response in patients.
Hexamer Therapeutics Inc. (“HTI”) and Innovative Vaccine Technologies (“IVT”) announce they are collaborating to develop and manufacture a safe, highly scalable and effective novel type of COVID-19 vaccine. This joint effort utilizes HTI’s revolutionary patented vaccine technology consisting of a novel self-assembling vaccine (strings of natural amino acids) combined with an adjuvant proven safe for the elderly, the vaccine sensitive, and the immune compromised.